Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).

Abstract

BACKGROUND:

Clinical benefit of neoadjuvant immunotherapy in resectable esophageal squamous cell carcinoma (ESCC). remains unclear. This study evaluated the efficacy and safety of the programmed death 1 (PD-1) inhibitor tislelizumab combined with chemotherapy as neoadjuvant therapy in patients with resectable ESCC.

METHODS:

Treatment-naïve patients were enrolled and eligible patients received 3 cycles of neoadjuvant therapy with tislelizumab, carboplatin, and nab-paclitaxel. The primary endpoint was surgery patients major pathological response (MPR). Subgroup analysis was stratified by tumor downstaging, circumferential resection margin (CRM), PD-ligand 1 (PD-L1) expression, and tumor mutation burden (TMB). Safety was assessed by adverse events (AEs) and postoperative complications.

RESULTS:

Between September 2020 and March 2021, 45 patients were enrolled. Thirty-six (80.0%) of 45 patients underwent surgery, and 29 (80.5%) underwent successful R0 resection. MPR and pathological complete response (pCR) for surgery patients were 72.0% and 50.0%, respectively. Intention to treatment (ITT) patients MPR and PCR were 57.5% and 40%. Downgrading occurred in 75% of 36 patients. MPR and pCR were identified to be associated with tumor downstaging and CRM but not PD-L1 expression or TMB. TPS levels in MPR and pCR group were significantly higher than that in Non-MPR and Non-pCR group, respectively. Treatment-related AEs of grade 3-4 and immune-related AEs occurred in 42.2% and 22.2% of 45 patients, respectively, and postoperative complications occurred in 77.8% of 36 patients. No treatment-related surgical delay or death occurred. No associations between gene mutation and pathological efficacy were observed.

CONCLUSIONS:

Tislelizumab plus chemotherapy as neoadjuvant therapy demonstrates promising antitumor activity for resectable ESCC with high rates of MPR, pCR, and R0 resection, as well as acceptable tolerability.

• Authors: Xiaolong Yan, Hongtao Duan, Yunfeng Ni, Yongan Zhou, Xiaoping Wang, Haini Qi, Li Gong, Honggang Liu, Feng Tian, Qiang Lu, Jianyong Sun, Ende Yang, Daixing Zhong, Tao Wang, Lijun Huang, Jian Wang, Chaoyang Wang, Yuanyong Wang, Zhiyi Wan, Jie Lei, Jinbo Zhao, Tao Jiang
• Journal: International journal of surgery (London, England) (Int J Surg) Vol. 103 Pg. 106680 (Jul 2022) ISSN: 1743-9159 [Electronic] United States
• PMID: 35595021 (Publication Type: Clinical Trial, Phase II, Journal Article)
• Copyright: Copyright © 2022. Published by Elsevier Ltd.

Chemical References

• Antibodies, Monoclonal, Humanized
• tislelizumab

Topics

• Antibodies, Monoclonal, Humanized
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Esophageal Neoplasms (drug therapy, surgery)
• Esophageal Squamous Cell Carcinoma (drug therapy, surgery)
• Humans
• Neoadjuvant Therapy (adverse effects)
• Postoperative Complications (etiology)
• Prospective Studies